.png){kind=icon}
.png){kind=icon}
Return
Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis
.png){kind=icon}
OA
AI
A
G
P
S
D
Y
J
C
T
DOI：10.3389/fonc.2026.1903818.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
BackgroundTagraxofusp is a first-in-class CD123-targeted therapy approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although venetoclax is not approved for BPDCN; limited use has been reported. We evaluated overall survival (OS) and healthcare resource utilization in patients with BPDCN treated with tagraxofusp- or venetoclax-based regimens in a US real-world setting.MethodsClaims data were analyzed from patients with ≥1 BPDCN diagnosis (January 2016-December 2023) and initiation of tagraxofusp- or venetoclax-based therapy. Index date was defined as first inpatient tagraxofusp dosing or venetoclax-based therapy initiation. Patients were matched 1:1 by line of therapy (LOT).ResultsEach cohort had 47 patients. Tagraxofusp-based treatment was associated with longer median OS versus venetoclax-based (35.3 vs 10.5 months); consistent across patients receiving monotherapy; combination; or transplantation. Tagraxofusp-treated patients were more likely to proceed to subsequent LOT versus venetoclax-treated (47% vs 11%). During months 2-6; tagraxofusp reduced median inpatient hospitalization duration (3 vs 7 days) and transfusion rates (3% vs 32%) versus venetoclax.ConclusionIn this retrospective claims-based analysis; tagraxofusp was associated with longer survival versus venetoclax; including across treatment contexts. These real-world results are consistent with the established role of tagraxofusp as the first-line standard of care for patients with BPDCN; irrespective of transplant eligibility; and support continued evaluation of tagraxofusp-based regimens as a backbone for future combinations.
Keywords:
venetoclax
real-world
survival
healthcare resource utilization
tagraxofusp
BPDCN
Journal
IF:
3.3
Papers:
3.4W
Citations:
9.5W
Organization
Cited Papers